Eptacog beta for the management of patients with haemophilia A and B with inhibitors: A European perspective
Haemophilia · 2024
DOI: 10.1111/hae.14944 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Haemophilia, 2024. Verfasst von Wolfgang Miesbach und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haemostaseology and Hemophilia Center, Medical Clinic 2, Institute of Transfusion Medicine, University Hospital Frankfurt, Frankfurt, G…. Hauptthemen laut MEDLINE: Factor VIIa, Hemophilia A. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Eptacog beta (activated), a recombinant human factor VIIa (rFVIIa), was approved by the US Food and Drug Administration (FDA) in 2020 (SEVENFACT®, LFB & HEMA Biologics) and the European Medicines Agency (EMA) in 2022 (CEVENFACTA®, LFB). In Europe, eptacog beta is indicated for the treatment of bleeds and the prevention of bleeds during surgery or invasive procedures in adults and adolescents (≥12 years old) with congenital haemophilia A or B with high‐titre inhibitors (≥5 BU) or with low‐titre inhibitors who are expected to have a high anamnestic response to factor VIII or factor IX, or to be refractory to increased dosing of these factors. The efficacy and safety of eptacog beta were evaluated in three Phase III clinical studies, PERSEPT 1, 2 and 3. For the EMA filing dossier, the analysis of data from PERSEPT 1 and 2 differed from the analysis used to support the filing in the US. In this review, we summarise current data regarding the mode of action, clinical efficacy and safety of eptacog beta for the management of haemophilia A and B in patients with inhibitors from a European perspective. In addition to providing a valuable summary of the analyses of the clinical data for eptacog beta conducted for the EMA, our review summarises the potential differentiators for eptacog beta compared with other current bypassing agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Haemostaseology and Hemophilia Center, Medical Clinic 2, Institute of Transfusion Medicine, University Hospital Frankfurt, Frankfurt, Germany.
- The Hospital for Sick Children and University of Toronto, Toronto, Canada.
- Haemophilia Comprehensive Care Centre, Faculty of Health Sciences, University of the Witwatersrand and National Health Laboratory Service, Johannesburg, South Africa.
- Clinical Haemostasis Unit and Lyon Haemophilia Centre, Louis Pradel Hospital, Lyon, France.
- Hospital Universitario La Paz-IdiPaz, Autónoma University, Madrid, Spain.
- Haemostasis and Thrombosis Unit, Division of Haematology, Cliniques Universitaires Saint-Luc, Université catholique de Louvain (UCLouvain), Brussels, Belgium.
ORCID-Profile: Wolfgang Miesbach, Manuel Carcao, Johnny Mahlangu
Zitieren
APA
Miesbach, W., Carcao, M., Mahlangu, J., Dargaud, Y., Jimenez-Yuste, V., & Hermans, C. (2024). Eptacog beta for the management of patients with haemophilia A and B with inhibitors: A European perspective. Haemophilia. https://doi.org/10.1111/hae.14944
Vancouver
Miesbach W, Carcao M, Mahlangu J, Dargaud Y, Jimenez-Yuste V, Hermans C. Eptacog beta for the management of patients with haemophilia A and B with inhibitors: A European perspective. Haemophilia. 2024. doi:10.1111/hae.14944
BibTeX
@article{Miesbach2024,
author = {Miesbach, Wolfgang and Carcao, Manuel and Mahlangu, Johnny and Dargaud, Yesim and Jimenez-Yuste, Victor and Hermans, Cédric},
title = {Eptacog beta for the management of patients with haemophilia A and B with inhibitors: A European perspective},
journal = {Haemophilia},
year = {2024},
doi = {10.1111/hae.14944}
}
EUVIMED